Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice

NCT ID: NCT00782314

Last Updated: 2009-07-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-04-30

Study Completion Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We want to evaluate efficacy of Symbicort® Turbuhaler® (formoterol/budesonide) therapy for asthma in real life conditions. For this purpose we will include both patients that are treated with Symbicort® Turbuhaler® the "classical" maintenance only treatment approach as well as those treated with the SMART approach.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

patients with maintenance only treatment with Symbicort Turbuhaler for at least 1 month

No interventions assigned to this group

2

patients with SMART treatment with Symbicort Turbuhaler for at least 1 month

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients diagnosed with persistent asthma treated with Symbicort® Turbuhaler® in line with its label
* non-pregnant females
* existing maintenance only treatment with Symbicort® Turbuhaler® 80 μg/4,5 μg, 160 μg/4,5 μg or 320 μg/9 μg for at least 1 month
* existing SMART treatment with Symbicort® Turbuhaler® 80 μg/4,5 μg or 160 μg /4,5 μg for at least 1 month

Exclusion Criteria

* patients not being treated with Symbicort® Turbuhaler®
* patients treated with Symbicort® Turbuhaler® for COPD
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca UK Limited, Branch Office in Slovenia

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Igor Koren, MD, MSc

Role: PRINCIPAL_INVESTIGATOR

Radix - medicinske storitve, Igor Koren s.p.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Celje, Celje, Slovenia

Site Status

Research Site

Dvorec Sela, Dvorec Sela, Slovenia

Site Status

Research Site

Grosuplje, Grosuplje, Slovenia

Site Status

Research Site

Idrija, Idrija, Slovenia

Site Status

Research Site

Izola, Izola, Slovenia

Site Status

Research Site

Jesenice, Jesenice, Slovenia

Site Status

Research Site

Kamnik-Duplica, Kamnik-Duplica, Slovenia

Site Status

Research Site

Kranj, Kranj, Slovenia

Site Status

Research Site

Litija, Litija, Slovenia

Site Status

Research Site

Ljubljana, Ljubljana, Slovenia

Site Status

Research Site

Lucija, Lucija, Slovenia

Site Status

Research Site

Maribor, Maribor City Municipality, Slovenia

Site Status

Research Site

Novo Mesto, Mestna Občina Novo mesto, Slovenia

Site Status

Research Site

Murska Sobota, Murska Sobota, Slovenia

Site Status

Research Site

Domžale, Občina Domžale, Slovenia

Site Status

Research Site

Ravne na Koroškem, Občina Ravne na Koroškem, Slovenia

Site Status

Research Site

Sežana, Občina Sežana, Slovenia

Site Status

Research Site

Ptuja, Ptuja, Slovenia

Site Status

Research Site

Slovenj Gradec, Slovenj Gradec, Slovenia

Site Status

Research Site

Slovenska Bistrica, Slovenska Bistrica, Slovenia

Site Status

Research Site

Topolšica, Topolsica, Slovenia

Site Status

Research Site

Velenje, Velenje, Slovenia

Site Status

Research Site

Vrhnika, Vrhnika, Slovenia

Site Status

Research Site

Zagorje, Zagorje, Slovenia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Slovenia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-RSI-SYM-2008/1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Local Phase 4 Pan-European SMART Study
NCT00463866 COMPLETED PHASE4